TITLE

ORION/UNIVERSITY OF GLASGOW TO IDENTIFY BIOMARKERS

PUB. DATE
March 2006
SOURCE
Worldwide Biotech;Mar2006, Vol. 18 Issue 3, p4
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the collaboration between Saint Louis, Missouri-based Orion Genomics and researchers to discover novel epigenetic biomarkers. Use of DNA methylation technologies to identify biomarkers; Research into epigenetic biomarkers to be conducted; Corporate background of Orion Genomics.
ACCESSION #
20451867

 

Related Articles

  • New breast cancer biomarkers could lead to better treatment.  // Medical Technology & Devices Week;12/31/2007, Vol. 5 Issue 51, p2 

    This article announces the discovery of new breast cancer biomarkers by Orion Genomics. The Orion study, which analyzed DNA methylation, was published in "PLoS ONE." According to Jared Ordway, director of research and development (R&D) at Orion, these biomarkers may be critical in the...

  • New breast cancer biomarkers may lead to improved treatment. Pedersen, Amanda // Medical Device Daily;12/26/2007, Vol. 11 Issue 233, p1 

    The article reports on the discovery of new breast cancer biomarkers by Orion Genomics that it says may someday lead to earlier detection and possibly better treatment of cancer. The company claimed that it has discovered and validated the most frequent DNA alterations detected in breast cancer....

  • MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma.  // BMC Cancer;2012, Vol. 12 Issue 1, p218 

    The article discusses a study conducted to know the importance of promoter methylation of newly identified epigenetically silenced genes (GATA6, CD81) and revealing its relationship with epigenetic markers to understand glioblastoma biology. It has been informed that the study results found that...

  • Molecular Analysis of a Multistep Lung Cancer Model Induced by Chronic Inflammation Reveals Epigenetic Regulation of p16 and Activation of the DNA Damage Response Pathway. Blanco, David; Vicent, Silvestre; Fraga, Mario F.; Fernandez-Garcia, Ignacio; Freire, Javier; Lujambio, Amaia; Esteller, Manel; Ortiz-de-Solorzano, Carlos; Pio, Ruben; Lecanda, Fernando; Montuenga, Luis M. // Neoplasia;Oct2007, Vol. 9 Issue 10, p840 

    The molecular hallmarks of inflammation-mediated lung carcinogenesis have not been fully clarified, mainly due to the scarcity of appropriate animal models. We have used a silica-induced multistep lung carcinogenesis model driven by chronic inflammation to study the evolution of molecular...

  • Cancer epigenetics reaches mainstream oncology. Rodríguez-Paredes, Manuel; Esteller, Manel // Nature Medicine;Mar2011, Vol. 17 Issue 3, p330 

    Epigenetics is one of the most promising and expanding fields in the current biomedical research landscape. Since the inception of epigenetics in the 1940s, the discoveries regarding its implications in normal and disease biology have not stopped, compiling a vast amount of knowledge in the past...

  • Pancreatic Cancer Biomarkers and Their Implication in Cancer Diagnosis and Epidemiology. Verma, Mukesh // Cancers;2010, Vol. 2 Issue 4, p1830 

    Pancreatic cancer is the fourth most common cause of cancer-related mortality in the United States. Biomarkers are needed to detect this cancer early during the disease development and for screening populations to identify those who are at risk. In cancer, "biomarker" refers to a substance or...

  • Expression of UCH-L1 in PETs and its Implications. Chen, Y. J.; Qiao, X. V.; Tang, L.; Wan, Y. H.; Lu, C. M.; Chen, J. // Neuroendocrinology;Jul2012 Supplement, Vol. 96, p1 

    Introduction: There is a lack of reliable biomarkers to distinguish benign from malignancy in pancreatic endocrine tumors (PETs) and to predict prognosis. Our previous study on insulinoma found the expression of UCH-LI in these tumors. The diagnostic or prognostic value of this protein has not...

  • Separating good from bad. McMahon, Karen // Farm Industry News;Mid-Feb2000, Vol. 33 Issue 3, p53 

    Informs on the technology called GeneThresher, developed by Orion Genomics, which accelerates the process of gene discovery and analysis. Use on crops; Faster delivery of new plant technology to market; Cheaper and faster gene discovery leading to more new products.

  • Recent Patents and Advances in Genomic Biomarker Discovery for Colorectal Cancers. Chen, Qiyun; Ye, Zhiyun; Lin, Sheng-Cai; Lin, Biaoyang // Recent Patents on DNA & Gene Sequences;Jun2010, Vol. 4 Issue 2, p86 

    Colorectal cancer (CRC) is the third most common cancer in the world. Early diagnosis of colorectal cancer is the key to reducing the death rate of CRC patients. Predicting the response to current therapeutic modalities of CRC will also have a great impact on patient care. This review summarizes...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics